Heng‐Huan Lee

7.9k total citations · 3 hit papers
56 papers, 3.4k citations indexed

About

Heng‐Huan Lee is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Heng‐Huan Lee has authored 56 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Molecular Biology, 29 papers in Oncology and 19 papers in Immunology. Recurrent topics in Heng‐Huan Lee's work include CAR-T cell therapy research (9 papers), Lymphoma Diagnosis and Treatment (8 papers) and Immunotherapy and Immune Responses (7 papers). Heng‐Huan Lee is often cited by papers focused on CAR-T cell therapy research (9 papers), Lymphoma Diagnosis and Treatment (8 papers) and Immunotherapy and Immune Responses (7 papers). Heng‐Huan Lee collaborates with scholars based in United States, Taiwan and China. Heng‐Huan Lee's co-authors include Mien‐Chie Hung, Jennifer L. Hsu, Weiya Xia, Ying‐Nai Wang, Hirohito Yamaguchi, Chia‐Wei Li, Dihua Yu, Wen-Hsuan Yu, Gabriel N. Hortobágyi and Jung-Mao Hsu and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

Heng‐Huan Lee

53 papers receiving 3.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression

2017 768 citations Shiping Jiao, Weiya Xia et al. Clinical Cancer Research profile →
p53 regulates epithelial–mesenchymal transition and stem cell properties through modulating miRNAs

2011 606 citations Weiya Xia, Chia‐Wei Li et al. profile →
TYRO3 induces anti–PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis

2021 255 citations Zhou Jiang, Seung-Oe Lim et al. Journal of Clinical Investigation profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Heng‐Huan Lee United States	23	1.9k	1.8k	831	795	531	56	3.4k
János L. Tanyi United States	36	1.7k 0.9×	1.9k 1.0×	887 1.1×	720 0.9×	378 0.7×	113	3.9k
Todd VanArsdale United States	27	1.4k 0.7×	1.7k 0.9×	1.0k 1.2×	617 0.8×	672 1.3×	48	3.7k
Argun Akçakanat United States	26	1.4k 0.8×	1.4k 0.8×	600 0.7×	568 0.7×	525 1.0×	52	2.9k
Michael Hölzel Germany	33	1.7k 0.9×	2.2k 1.2×	1.3k 1.6×	588 0.7×	443 0.8×	96	4.3k
Marion Dorsch United States	32	1.2k 0.6×	2.2k 1.2×	889 1.1×	591 0.7×	345 0.6×	55	3.7k
David A. Barbie United States	30	2.2k 1.2×	2.7k 1.5×	1.4k 1.7×	628 0.8×	630 1.2×	81	5.0k
Tiziana Triulzi Italy	30	1.4k 0.7×	1.7k 0.9×	713 0.9×	1.2k 1.5×	345 0.6×	61	3.3k
Jennifer L. Hsu United States	29	2.4k 1.2×	2.7k 1.5×	1.7k 2.0×	1.3k 1.6×	791 1.5×	62	5.1k
Su Yin Lim Australia	28	1.6k 0.8×	1.3k 0.7×	1.4k 1.6×	474 0.6×	415 0.8×	50	3.1k
Anthony J. Olszanski United States	29	2.6k 1.4×	1.6k 0.9×	1.3k 1.6×	443 0.6×	848 1.6×	156	4.1k

Countries citing papers authored by Heng‐Huan Lee

Since Specialization

Citations

This map shows the geographic impact of Heng‐Huan Lee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heng‐Huan Lee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heng‐Huan Lee more than expected).

Fields of papers citing papers by Heng‐Huan Lee

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heng‐Huan Lee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heng‐Huan Lee. The network helps show where Heng‐Huan Lee may publish in the future.

Co-authorship network of co-authors of Heng‐Huan Lee

This figure shows the co-authorship network connecting the top 25 collaborators of Heng‐Huan Lee. A scholar is included among the top collaborators of Heng‐Huan Lee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Heng‐Huan Lee. Heng‐Huan Lee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lee, Heng‐Huan, Violetta V. Leshchenko, Ravi Prakash Shukla, et al.. (2025). SOX11 modulates BCR signaling through the PAX5/CD19 axis for therapeutic targeting in BTK-resistant mantle cell lymphoma. Blood Advances. 9(24). 6267–6278.

Li, Yijing, Changying Jiang, Fangfang Yan, et al.. (2025). BCL-2/BCL-XL dual inhibition triggers Gasdermin D-mediated pyroptosis in mantle cell lymphoma. Cancer Letters. 632. 217961–217961.

Lee, Heng‐Huan, Ravi Prakash Shukla, Violetta V. Leshchenko, et al.. (2024). Novel Insights into SOX11 Modulation of BCR Signaling and Targeting of BTK Resistance. Blood. 144(Supplement 1). 1402–1402. 1 indexed citations

Lee, Heng‐Huan, Violetta V. Leshchenko, Ravi Prakash Shukla, et al.. (2024). Abstract 649: SOX11 regulates BCR signaling via the PAX5/CD19 axis in MCL. Cancer Research. 84(6_Supplement). 649–649. 1 indexed citations

Wang, Ying‐Nai, Heng‐Huan Lee, Zhou Jiang, et al.. (2023). Ribonuclease 1 Enhances Antitumor Immunity against Breast Cancer by Boosting T cell Activation. International Journal of Biological Sciences. 19(10). 2957–2973. 9 indexed citations

Che, Yuxuan, Yang Liu, Yijing Li, et al.. (2023). Dual targeting of CDK4/6 and Bcl-2 exhibits a potent antitumor effect on mantle cell lymphoma. Blood Advances. 7(14). 3361–3365. 1 indexed citations

Wang, Ying‐Nai, Heng‐Huan Lee, Yongkun Wei, et al.. (2022). An optimized protocol for PD-L1 pathological assessment with patient sample deglycosylation to improve correlation with therapeutic response. STAR Protocols. 3(1). 101198–101198. 5 indexed citations

Jiang, Zhou, Seung-Oe Lim, Meisi Yan, et al.. (2021). TYRO3 induces anti–PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis. Journal of Clinical Investigation. 131(8). 255 indexed citations breakdown →

Sun, Linlin, Chia-Wei Li, Ezra M. Chung, et al.. (2020). Targeting Glycosylated PD-1 Induces Potent Antitumor Immunity. Cancer Research. 80(11). 2298–2310. 133 indexed citations

10.

Lee, Heng‐Huan, Ying‐Nai Wang, Weiya Xia, et al.. (2019). Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy. Cancer Cell. 36(2). 168–178.e4. 282 indexed citations

11.

Jiao, Shiping, Weiya Xia, Hirohito Yamaguchi, et al.. (2017). PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. Clinical Cancer Research. 23(14). 3711–3720. 768 indexed citations breakdown →

12.

Chen, Leon, et al.. (2017). Treatment of Advanced Basal Cell Carcinoma with Sonidegib: Perspective from the 30-Month Update of the BOLT Trial. Future Oncology. 14(6). 515–525. 23 indexed citations

13.

Lim, Seung-Oe, Chia‐Wei Li, Weiya Xia, et al.. (2016). EGFR Signaling Enhances Aerobic Glycolysis in Triple-Negative Breast Cancer Cells to Promote Tumor Growth and Immune Escape. Cancer Research. 76(5). 1284–1296. 203 indexed citations

14.

Chou, Chao‐Kai, Heng‐Huan Lee, Chun‐Te Chen, et al.. (2014). mMAPS: A Flow-Proteometric Technique to Analyze Protein-Protein Interactions in Individual Signaling Complexes. Science Signaling. 7(315). rs1–rs1. 7 indexed citations

15.

Lee, Heng‐Huan, Frank J. Lowery, Yekaterina B. Khotskaya, et al.. (2013). Inhibition of Type I Insulin-Like Growth Factor Receptor Signaling Attenuates the Development of Breast Cancer Brain Metastasis. PLoS ONE. 8(9). e73406–e73406. 29 indexed citations

16.

Wang, Ying‐Nai, Heng‐Huan Lee, Hong-Jen Lee, et al.. (2012). Membrane-bound Trafficking Regulates Nuclear Transport of Integral Epidermal Growth Factor Receptor (EGFR) and ErbB-2. Journal of Biological Chemistry. 287(20). 16869–16879. 62 indexed citations

17.

Chen, Chun‐Te, Hirohito Yamaguchi, Hong-Jen Lee, et al.. (2011). Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase. Molecular Cancer Therapeutics. 10(8). 1327–1336. 21 indexed citations

18.

Chou, Chao‐Kai, Nan Jing, Hirohito Yamaguchi, et al.. (2010). High speed digital protein interaction analysis using microfluidic single molecule detection system. Lab on a Chip. 10(14). 1793–1793. 9 indexed citations

19.

Wang, Ying‐Nai, Hongmei Wang, Hirohito Yamaguchi, et al.. (2010). COPI-mediated retrograde trafficking from the Golgi to the ER regulates EGFR nuclear transport. Biochemical and Biophysical Research Communications. 399(4). 498–504. 98 indexed citations

20.

Chou, Chao‐Kai, Nan Jing, Hirohito Yamaguchi, et al.. (2010). Rapid detection of two-protein interaction with a single fluorophore by using a microfluidic device. The Analyst. 135(11). 2907–2907. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact